🔎 Trials Near Me

Home › Multiple Myeloma › NCT03858205

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

Recruiting

Phase II Multi-Institutional Study of Low-Dose (2Gy) Palliative Radiotherapy in the Treatment of Symptomatic Bone Metastases From Multiple Myeloma

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Histologic diagnosis of multiple myeloma
* Painful bone metastasis (index lesion) that has a radiographic correlate
* Patient may have had any number of prior chemotherapy/immunotherapy regimens (changes to systemic therapy or use of bisphosphonates for 4 weeks before and after RT are allowed, but recording of these changes must be made so it can be accounted for)
* Eastern Cooperative Oncology Group (ECOG) 0-2
* Brief Pain Inventory (BPI) score \>= 2
* Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

* Patients will be ineligible if the index lesion has received prior radiation therapy or prior palliative surgery. Patients may have received prior palliative or primary radiotherapy or surgery to other parts of the body, as long as the index lesion was not in the prior radiation fields and has not received prior palliative surgery
* Patients will also be ineligible if there is pathologic fracture or impending fracture at the site of the index lesion or planned surgical fixation of the bone at the index lesion
* Patients with clinical or radiographic evidence of spinal cord or cauda equina compression/effacement from the index lesion, and/or with index lesions located at the skull base or orbital lesions
* Patients must not be pregnant

About the study

This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.

What is being tested

Sponsor: University of Southern California · Participants: 100 · Started: Mar 11, 2019

Contact the study team

Official record on ClinicalTrials.gov — NCT03858205

Locations in the U.S.

CaliforniaCity of Hope, Duarte
Cedars Sinai Medical Center, Los Angeles
Los Angeles General Medical Center, Los Angeles
USC / Norris Comprehensive Cancer Center, Los Angeles
GeorgiaEmory University Hospital/Winship Cancer Institute, Atlanta
MassachusettsDana-Farber Cancer Institute, Boston
MinnesotaUniversity of Minnesota - Masonic Cancer Center, Minneapolis
New YorkIcahn School of Medicine at Mount Sinai, New York
PennsylvaniaUniversity of Pennsylvania/Abramson Cancer Center, Philadelphia

Conditions

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.